|Bid||8.80 x 2900|
|Ask||8.84 x 1000|
|Day's Range||8.77 - 9.12|
|52 Week Range||6.26 - 27.50|
|Beta (3Y Monthly)||2.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 20, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.14|
Below are several biotech companies in the news you should know HENDERSON, NV / ACCESSWIRE / February 12, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX) , a life sciences ...
The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 7.) Array Biopharma Inc (NASDAQ: ARRY ) Down In The Dumps (Biotech ...
Sangamo's zinc finger nucleases are competing with another technology, known as CRISPR, to show which one is most accurate and efficient in snipping genes and replacing the cut-out section with a correct version.
Sangamo said SB-318 zinc finger nuclease, or ZFN, which is being evaluated in a Phase 1/2 study dubbed EMPOWERS in patients with mild mucopolysaccharides Type 1, or MPS 1, receiving weekly enzyme replacement therapy, or ERT, suggested a dose-dependent increase in leukocyte alpha-L-iduronidase, or IDUA, enzyme activity. Plasma IDUA activity was unchanged from the baseline in all three patients studied, while baseline urine GAG measurements were at or slightly above normal.
Interim results from Sangamo’s “Champions” study suggest that gene-edited liver cells can generate a missing enzyme in patients with the disease known as MPS II, but they don’t appear to be producing enough to be beneficial.
Scientists think they have achieved the first gene editing inside the body, altering DNA in adults to try to treat a disease, although it's too soon to know if this will help.
- Liver biopsy analysis detected targeted integration of IDS transgene, providing preliminary molecular evidence of in vivo genome editing in humans - Plasma enzyme activity suggests genome-edited liver ...
BRISBANE, Calif., Feb. 7, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today presented interim data from the Phase 1/2 EMPOWERS Study evaluating the SB-318 zinc finger nuclease (ZFN) in vivo (inside the body) genome editing product candidate in patients with Mucopolysaccharidosis Type I (MPS I). Sangamo believes data from these two studies provide complementary evidence supportive of a favorable safety profile and of the activity of the ZFN in vivo genome editing technology used in both SB-318 and SB-913.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 6) Array Biopharma Inc (NASDAQ: ARRY ) Millendo Therapeutics ...
BRISBANE, Calif., Feb. 1, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will host a conference call on February 7 th at 12:30 ...
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Sandy Macrae has been the CEO of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) since 2016. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at Read More...
RICHMOND, Calif., Jan. 22, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, today announced the appointment of Adrian Woolfson, BM BCh, PhD, as Executive Vice President of Research and Development, effective January 22, 2019. Dr. Woolfson will oversee discovery, research and development activities for the Company and will report to Sandy Macrae.
In this daily bar chart of SGMO, below, we can see that prices were in a downtrend from February to a low in November. In the lower panel is the 12-day price momentum study which shows improving momentum lows from November to December versus equal lows in price.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said there was really no reason for a sell-off in Brink's Company (NYSE: BCO ). He thinks the quarter was great and he wants to buy the stock. ...
Jim Cramer shares his responses to callers' stock questions, including that of an automaker that recently lost its leader.
Sangamo Therapeutics (SGMO) is the leader in gene editing, and an unappreciated leader in gene therapy as well; with many value drivers coming in 2019, the stock is our top speculative pick for the coming year, explains Jay Silverman, analyst with The Medical Technology Stock Letter.
RICHMOND, Calif., Jan. 4, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that Sandy Macrae , CEO of Sangamo, will present a corporate overview at the 37 th Annual J.P. Morgan ...
RICHMOND, Calif., Jan. 4, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) announced today that interim clinical data from the Company's inherited metabolic diseases development programs will be presented at WORLDSymposium, an annual conference dedicated to lysosomal diseases being held February 4-8th, 2019 at the Hyatt Regency Orlando in Orlando, Florida. The SB-318 (MPS I) presentation is expected to describe the scientific rationale for SB-318, the clinical trial design, and preliminary safety and biochemical measurements at up to four weeks from the first three patients enrolled in the EMPOWERS Study.
Who Is Eyeing Sangamo Therapeutics Now?(Continued from Prior Part)Earnings trends In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.